Pulse Biosciences COO Liane Teplitsky buys $99,965 in stock

Chief Operating Officer Liane Teplitsky of Pulse Biosciences, Inc. (PLSE) bolstered her stake in the company by acquiring 2,070 shares of common stock through open market purchases. The transactions, detailed in a Form 4 filing with the Securities and Exchange Commission, occurred on August 26 and August 28, 2026, with Teplitsky purchasing 1,036 shares at $48.235 per share and an additional 1,034 shares at $48.35 per share, respectively.

These purchases, executed within a designated trading window and complying with securities laws, transpired at prices reflective of open market transactions facilitated by a broker-dealer. The move comes as PLSE's stock hovers near its 52-week high of $50.90, having achieved a significant 206% return over the preceding year. Despite this bullish outlook, InvestingPro's assessment indicates the stock is currently overvalued, ranking among companies identified as Most Overvalued.

For a comprehensive analysis, including valuation insights and 15 ProTips, subscribers can access the Pro Research Report. Meanwhile, Pulse Biosciences has faced mixed financial results, reporting a second-quarter loss that surpassed expectations, with an adjusted loss of $0.36 per share against the forecasted $0.28, while revenue lagged behind projections, amounting to $400,000 compared to the predicted $600,000.

Despite these challenges, investor confidence remains buoyed by the acceleration in enrollment for the company's critical atrial fibrillation trial and advancements in thyroid and surgical initiatives. Furthermore, financial analysts have taken note of the company's innovative Nanosecond Pulsed Field Ablation technology, with Needham assigning a "Buy" rating and setting a price target of $58, while Canaccord has increased its target price from $32 to $43, maintaining a Buy recommendation, citing advancements in clinical and regulatory domains.